Findings

What do systematic reviews say?

3,234 questions · 3,357 findings · 396 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 803 · 23.9%GRADE not reported 270 · 8%Very low 757 · 22.5%Low 859 · 25.6%Moderate 486 · 14.5%High 182 · 5.4%

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25480 participants
High

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Severe or critical COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

All‐cause mortalityÂ

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Systemic reactogenicity events

WIBP‐CorV – Sinopharm‐Wuhan showed no clear difference in systemic reactogenicity eventse compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.99 [0.95, 1.03]
2 studies · 27029 participants
High

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Any adverse eventh

WIBP‐CorV – Sinopharm‐Wuhan leads to lower any adverse eventh compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.96 [0.93, 0.98]
2 studies · 27029 participants
High

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Serious adverse eventsi

WIBP‐CorV – Sinopharm‐Wuhan showed no clear difference in serious adverse eventsi compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.83 [0.6, 1.15]
2 studies · 27029 participants
Low

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Local reactogenicity events

WIBP‐CorV – Sinopharm‐Wuhan leads to lower local reactogenicity eventsk compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.88 [0.85, 0.92]
2 studies · 27029 participants
High

Lisinopril (0.7 mg/kg daily) vs losartan (0.7 mg/kg daily)

Cardiac function · patients with established cardiomyopathy in DMD

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Lisinopril (0.7 mg/kg daily) vs losartan (0.7 mg/kg daily)

Size of metabolically abnormal areas of myocardium · patients with established cardiomyopathy in DMD

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lisinopril (0.7 mg/kg daily) vs losartan (0.7 mg/kg daily)

Improvements in quality of life measures · patients with established cardiomyopathy in DMD

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lisinopril (0.7 mg/kg daily) vs losartan (0.7 mg/kg daily)

Adverse events · patients with established cardiomyopathy in DMD

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Salivary Actinobacillus level vs Not specified

Salivary S. mutans level · Patients with aggressive periodontitis

Salivary Actinobacillus and S. mutans levels were negatively associated.

1 finding from 1 review

Association between periodontitis and dental caries: a systematic review and meta-analysis. 2024 All outcomes
Overall
OR 0.08 [0.01, 0.85]
1 study
GRADE not reported

Regimens containing quinolone vs regimens containing cephalosporin

Clinical cure according to criteria established by study authors Severe PID · women with PID

Regimens containing quinolone showed no clear difference in clinical cure according to criteria established by study authors… compared with regimens containing cephalosporins (low certainty).

1 finding from 1 review

Antibiotic therapy for pelvic inflammatory disease 2020 · Cochrane Headline outcomes only
RR 1.06 [0.91, 1.23]
Studies not reported
Low

Regimens containing quinolone vs regimens containing cephalosporin

Adverse events: any antibiotic‐related adverse event leading to discontinuation of therapy · women with PID

It is very uncertain whether regimens containing quinolone changes adverse events: any antibiotic‐related adverse event leading to… compared with regimens containing cephalosporins (very low certainty).

1 finding from 1 review

Antibiotic therapy for pelvic inflammatory disease 2020 · Cochrane Headline outcomes only
RR 2.24 [0.52, 9.72]
Studies not reported
Very low

Regimens containing quinolone vs regimens containing cephalosporin

Microbiological clearance · women with PID

It is very uncertain whether regimens containing quinolone changes microbiological clearance compared with regimens containing cephalosporins (very low certainty).

1 finding from 1 review

Antibiotic therapy for pelvic inflammatory disease 2020 · Cochrane Headline outcomes only
RR 0.95 [0.84, 1.08]
Studies not reported
Very low

Regimens containing quinolone vs regimens containing cephalosporin

Laparoscopic evidence of resolution of PID based on physician opinion · women with PID

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic therapy for pelvic inflammatory disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Regimens containing quinolone vs regimens containing cephalosporin

Length of stay · women with PID

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic therapy for pelvic inflammatory disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Regimens containing quinolone vs regimens containing cephalosporin

Fertility outcome · women with PID

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic therapy for pelvic inflammatory disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Regimens containing quinolone vs regimens containing cephalosporin

Clinical cure according to criteria established by study authors Mild‐moderate PID · women with PID

Regimens containing quinolone showed no clear difference in clinical cure according to criteria established by study authors… compared with regimens containing cephalosporins (low certainty).

1 finding from 1 review

Antibiotic therapy for pelvic inflammatory disease 2020 · Cochrane Headline outcomes only
RR 1.05 [0.98, 1.14]
Studies not reported
Low

Fluocinonide in adhesive base vs placebo

Physician Global Assessment (clinical signs, complete response) · People with erosive oral lichen planus

Fluocinonide in adhesive base showed no clear difference in physician Global Assessment (clinical signs, complete response) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
RR 4.67 [0.24, 88.96]
1 study · 27 participants
GRADE not reported